Clinical Trials in Ohio

Showing 6441-6460 of 15,929 trials

A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.

NCT04179409

This is an 48-week open-label study to determine the efficacy and safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 for the treatment of boys with duchenne muscular dystrophy who have a single exon duplication of either exon 45, 51 or 53, respectively. There will be weekly infusions and two muscle biopsies at baseline and at month 12.

Duchenne Muscular Dystrophy

Kevin Flanigan3 participantsStarted Feb 2020

Columbus, Ohio, United States

COMPLETEDPhase 232 miles

Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma

NCT02484443

This phase II trial studies how well dinutuximab works when given with sargramostim in treating patients with osteosarcoma that has come back after treatment (recurrent). Monoclonal antibodies, such as dinutuximab, may find tumor cells and help kill them. Sargramostim may help the body increase the amount of white blood cells it produces, which help the body fight off infections. Giving dinutuximab with sargramostim may work better and kill more cancer cells.

Metastatic Malignant Neoplasm in the LungMetastatic OsteosarcomaRecurrent Osteosarcoma

National Cancer Institute (NCI)41 participantsStarted Feb 2016

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Little Rock, Arkansas, United States +127 more locations

A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.

Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma

Find Trials by Condition in Ohio

Active Ingredients & Efficacy of Aquatic Therapy for Autistic Children

Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

Volume Optimization Incorporating Negative Pressure Diuresis in Heart Failure (VOID-HF)

A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults

Developmental Impact of NICU Exposures (DINE)

A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer

A Prospective Study to Evaluate the ConforMIS iTotal® (PS) Knee Replacement System

Study of the ConforMIS iDuo(R) G2

Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects

Multi-Center Study to Evaluate the ConforMIS iUni Knee Implant

A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System

A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

Alignment Comparison Between TruMatch™ Personalized Solutions and Conventional Total Knee Replacement Instrumentation

A Retrospective Study of the iTotal CR Knee Replacement System

Evaluating the Analytical Equivalency of Serum and Whole Blood Samples Run on the MeMed Key® Platform (Perseverance Study)

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

Identification of Clinically Insignificant or Significant Prostate Cancer With the miR Scientific Sentinel™ Platform